Work

Overcoming Chemotherapy Resistance in Prostate Cancer

Year: 2011

Type: article

Abstract: Although treatment for prostate cancer has improved over the past several years, taxanes remain the only form of chemotherapy that improves survival in patients with metastatic castration-resistant prostate cancer (mCRPC). In addition to the promising therapeutic cancer vaccines and newly developed agents targeting androgen receptor signaling, chemotherapy-based treatments will likely continue to play a significant role in patients with mCRPC. Recently published data that showed that a second taxane (cabazitaxel) extends survival after progression on docetaxel was a significant step forward, but also highlighted the need to overcome taxane resistance in prostate cancer. Preliminary evidence suggests that several treatment strategies may improve the activity of taxanes in prostate cancer and perhaps enhance clinical outcomes.

Source: Clinical Cancer Research

DOI: 10.1158/1078-0432.ccr-10-2654

Authors: Ravi A. Madan, Sumanta Kumar Pal, Oliver Sartor, William L. Dahut

Institutions: Tulane University, City of Hope, National Cancer Institute

Language: English

Topic: Prostate Cancer Treatment and Research

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

Funders: National Institutes of Health, U.S. Food and Drug Administration, National Cancer Institute